[{"orgOrder":0,"company":"NHS England","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"NHS England","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NHS England \/ NHS England","highestDevelopmentStatusID":"15","companyTruncated":"NHS England \/ NHS England"},{"orgOrder":0,"company":"NHS England","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NHS England","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NHS England \/ NHS England","highestDevelopmentStatusID":"15","companyTruncated":"NHS England \/ NHS England"},{"orgOrder":0,"company":"NHS England","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"NHS England","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"NHS England \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"NHS England \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"NHS England","sponsor":"University of Manchester","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"||Cyclooxygenase","graph1":"Oncology","graph2":"Phase II","graph3":"NHS England","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NHS England \/ University of Manchester","highestDevelopmentStatusID":"8","companyTruncated":"NHS England \/ University of Manchester"},{"orgOrder":0,"company":"NHS England","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Inclisiran","moa":"||PCSK9 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"NHS England","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NHS England \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"NHS England \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"NHS England","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Inclisiran","moa":"PCSK9 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NHS England","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NHS England \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"NHS England \/ Novartis Pharmaceuticals Corporation"}]

Find Clinical Drug Pipeline Developments & Deals by NHS England

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : The agreement aims for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy (exagamglogene autotemcel).

                          Product Name : Casgevy

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 30, 2025

                          Lead Product(s) : Exagamglogene Autotemcel

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Recipient : Vertex Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : The agreement coincides with publication of the positive National Institute for Health and Care Excellence’s evaluation determination, which recognized the clinical impact and economic benefit of Libmeldy according to the institute’s Highly Specializ...

                          Product Name : Libmeldy

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 02, 2022

                          Lead Product(s) : Atidarsagene Autotemcel

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Recipient : Orchard Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Breast Cancer Now said successful results could lead to further clinical trials of aspirin and avelumab for incurable secondary triple negative breast cancer, which happens when cancer cells that started in the breast spread to other parts of the body.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 18, 2021

                          Lead Product(s) : Aspirin,Avelumab,Lansoprazole

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : University of Manchester

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Agreement follows positive NICE recommendation and commits to deliver Leqvio® (inclisiran) access via a population health management approach identifying eligible patients across England.

                          Product Name : Leqvio

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          January 09, 2021

                          Lead Product(s) : Inclisiran,Ezetimibe

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : As part of the agreement with NHS England, Vertex has committed to submit ORKAMBI®, SYMKEVI® and KAFTRIO® to the National Institute for Health and Care Excellence (NICE) within an agreed upon timetable, allowing for a period of real-world data collect...

                          Product Name : Kaftrio

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 30, 2020

                          Lead Product(s) : Ivacaftor,Elexacaftor,Tezacaftor

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase IV

                          Sponsor : Vertex Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : With this collaboration, Novartis aims to bring first-in-class cholesterol lowering drug via a world-first, population health model to large at risk NHS patient population with ACD.

                          Product Name : Leqvio

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          January 13, 2020

                          Lead Product(s) : Inclisiran

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank